BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q3 2020 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q3: 2020-11-05 Earnings Summary

EPS of $0.50 beats by $0.24
 | Revenue of $476.78M (3.40% Y/Y) beats by $22.15M

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET

Company Participants

Traci McCarty - VP, IR
Jean-Jacques Bienaimé - Chairman and CEO
Greg Guyer - EVP and Chief Technical Officer
Jeff Ajer - EVP and CCO
Henry Fuchs - President, Worldwide Research and Development
Brian Mueller - EVP, CFO

Conference Call Participants

Salveen Richter - Goldman Sachs
Cory Kasimov - JPMorgan
Robyn Karnauskas - SunTrust Securities
Chris Raymond - Piper Sandler
Martin Auster - Credit Suisse
Paul Matteis - Stifel
Philip Nadeau - Cowen and Company
Geoff Meacham - Bank of America Merrill Lynch
Akash Tewari - Wolfe Research
Matthew Harrison - Morgan Stanley
Gena Wang - Barclays
Gershell Leland - Oppenheimer

Operator

Ladies and gentlemen, thank you for standing-by and welcome to the BioMarin Third Quarter 2020 Financial Results Conference Call. Hosting the conference call today is from BioMarin, Traci McCarty, Vice President of Investor Relations. Please go ahead madam.

Traci McCarty

Thank you, Joana, and thank you all for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin’s filings with the SEC including 10-Q, 10-K and 8-K report.

On the call remotely, well, some are remote and some are sitting here together from BioMarin management today J.J. Bienaimé, Chairman and Chief Executive Officer; Jeff Ajer, Executive Vice President and Chief Commercial Officer; Hank Fuchs, President, Worldwide Research and Development; Greg Guyer, Executive Vice President and Chief Technical Officer and Brian Mueller, Executive Vice President and Chief Financial Officer. We

Recommended For You

About BMRN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BMRN